AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33307107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), single-dose intravenous infusion
Number of subjects: 30
Study 33307151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 fractions of 7.0 Gy
Number of subjects: 90
Study 33307151 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 fractions of 10.0 Gy
Number of subjects: 90
Study 33307151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 single fraction of 20.0 Gy
Number of subjects: 90
Study 33307151 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment schedules
Number of subjects: 90
Study 33307469 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CDR (≥11)
Number of subjects: 40
Study 33307491 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression with elastic net penalty
Number of subjects: 457
Study 33307491 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost tree
Number of subjects: 457
Study 33307491 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machines (SVM)
Number of subjects: 457
Study 33307491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 457
Study 33307957 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33308230 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on person-centered family planning for ASHAs
Number of subjects: 0
Study 33308230 — intervention group
Group type: COMPARATOR
Intervention: Control ASHAs (no specific intervention)
Number of subjects: 0
Study 33308240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic severe primary MR patients
Number of subjects: 120
Study 33308240 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic chronic severe primary MR patients
Number of subjects: 120
Study 33308240 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR derived ECV
Number of subjects: 120
Study 33308240 — intervention group
Group type: COMPARATOR
Intervention: Autopsy controls
Number of subjects: 120
Study 33308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 8 Gy in 1 fraction
Number of subjects: 34
Study 33308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 10 Gy in 1 fraction
Number of subjects: 34
Study 33308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 10 Gy in 2 fractions
Number of subjects: 34
Study 33308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 34
Study 33308277 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making process and surrogate decision-making processes in care planning.
Number of subjects: 0
Study 33308277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methodology (epidemiological and qualitative research) to explore opposition and refusal of care.
Number of subjects: 0
Study 33308307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glutamine
Number of subjects: 30
Study 33309060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic VENCH scoring system (V, E, N, C, H scores)
Number of subjects: 4
Study 33309459 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subanesthetic ketamine infusion
Number of subjects: 33
Study 33309581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 794
Study 33309978 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) alone, doses of 24 to 39.6 Gy
Number of subjects: 75
Study 33309978 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) alone
Number of subjects: 75
Study 33310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula 2 (FAHF-2)
Number of subjects: 0
Study 33310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive TCM therapy
Number of subjects: 0
Study 33310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple TCM therapy (ingestion, bath, and cream)
Number of subjects: 0
Study 33310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao Feng San and Japanese and Korean formulas
Number of subjects: 0
Study 33310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 33310655 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered bacteriophages with modified receptor-binding proteins
Number of subjects: 0
Study 33310655 — intervention group
Group type: EXPERIMENTAL
Intervention: Phages as prokaryotic gene therapy vectors
Number of subjects: 0
Study 33310655 — intervention group
Group type: EXPERIMENTAL
Intervention: Big data and AI-driven approaches for phage design
Number of subjects: 0
Study 33310795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low first dose of surfactant
Number of subjects: 0
Study 33310795 — intervention group
Group type: COMPARATOR
Intervention: High first dose of surfactant
Number of subjects: 0
Study 33310806 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-focused Boot Camp Translation (BCT) intervention
Number of subjects: 0
Study 33310814 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 outbreak period
Number of subjects: 6040
Study 33310814 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with stress worsening
Number of subjects: 6040
Study 33310883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients with GAD antibodies (9 out of 16 patients proceeded with surgery)
Number of subjects: 221
Study 33310883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients without GAD antibodies (112 out of 205 patients proceeded with surgery)
Number of subjects: 221
Study 33311588 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6870810
Number of subjects: 74
Study 33311959 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use during preconception and early pregnancy
Number of subjects: 1228
Study 33311959 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use detected at different gestational periods
Number of subjects: 1228
Study 33312142 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagering inducements (€10, €50, €100, or €200)
Number of subjects: 171
Study 33312142 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no incentive)
Number of subjects: 171
Study 33312759 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-133 T cell infusion
Number of subjects: 21
Study 33312766 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific stabilization exercise (SSE)
Number of subjects: 39
Study 33312766 — intervention group
Group type: COMPARATOR
Intervention: Traditional trunk exercise (TTE)
Number of subjects: 39
Study 33313307 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epithelial sodium channel inhibitor BI 1265162
Number of subjects: 0
Study 33313307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33314078 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 1960
Study 33314078 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1960
Study 33314716 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) radiomics using k-nearest neighbor (KNN) classifier
Number of subjects: 51
Study 33314716 — intervention group
Group type: COMPARATOR
Intervention: Standard institutional practice of radical radiotherapy (RT)
Number of subjects: 51
Study 33314747 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg plus apatinib combined with liposomal paclitaxel 150 mg/m²
Number of subjects: 30
Study 33314761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin co-administered with mefenamic acid (UGT inhibitor)
Number of subjects: 0
Study 33314761 — intervention group
Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 0
Study 33314761 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (MFA)
Number of subjects: 0
Study 33314777 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 blockade with canakinumab
Number of subjects: 1
Study 33314777 — intervention group
Group type: COMPARATOR
Intervention: Majeed syndrome
Number of subjects: 1
Study 33314777 — intervention group
Group type: COMPARATOR
Intervention: M2-like macrophages from the patient with Majeed syndrome
Number of subjects: 1
Study 33314777 — intervention group
Group type: COMPARATOR
Intervention: Accelerated osteoclastogenesis in the patient with Majeed syndrome
Number of subjects: 1
Study 33314777 — intervention group
Group type: EXPERIMENTAL
Intervention: JNK inhibition and IL-1 blockade
Number of subjects: 1
Study 33314979 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33315176 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning based automated system using EEG features
Number of subjects: 66
Study 33315277 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) therapy
Number of subjects: 36
Study 33315296 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo valve via transaxillary approach
Number of subjects: 75
Study 33315505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (Encage™)
Number of subjects: 20
Study 33315630 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPK pathway inhibitors
Number of subjects: 0
Study 33315630 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33315694 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 64
Study 33315720 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 0
Study 33315720 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition
Number of subjects: 0
Study 33315720 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study 33316105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 2819
Study 33316268 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 524
Study 33316268 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels (after adjustment for confounders)
Number of subjects: 524
Study 33316557 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line immunotherapy
Number of subjects: 636
Study 33316557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 636
Study 33316557 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy
Number of subjects: 636
Study 33316557 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 636
Study 33316557 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 636
Study 33317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of TSIH (TSIHc)
Number of subjects: 76
Study 33317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination for TSIH (TSIHu)
Number of subjects: 76
Study 33317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for risk factors
Number of subjects: 76
Study 33317530 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with a rapid decline in lung function
Number of subjects: 12
Study 33317530 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 12
Study 33317628 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring (measured twice a day for 7 days at 4, 8, and 12 weeks)
Number of subjects: 2483
Study 33317628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBP monitoring)
Number of subjects: 2483
Study 33317628 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring (among those who measured at least once)
Number of subjects: 2483
Study 33317628 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring
Number of subjects: 2483
Study 33317695 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine supplementation in T cells from old donors
Number of subjects: 0
Study 33317695 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous spermidine
Number of subjects: 0
Study 33317695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced antigen-specific CD8+ T cells
Number of subjects: 0
Study 33317695 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-induced T cells in older vaccinees
Number of subjects: 0
Study 33317729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine treatment (responders)
Number of subjects: 49
Study 33317858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (a Janus kinase 1/3 inhibitor)
Number of subjects: 5
Study 33318007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysine for inhalation solution (AZLI)
Number of subjects: 0
Study 33318012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (15 to 20 mg/kg/day)
Number of subjects: 105
Study 33318012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (40 mg/kg/day)
Number of subjects: 105
Study 33318012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (56 mg/kg/day)
Number of subjects: 105
Study 33318012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (20 to 25 mg/kg/day)
Number of subjects: 105
Study 33318014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 46
Study 33318032 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care bundle comprising: (1) ASQ for self-harm risk assessment, (2) HEADS-ED for mental health evaluations, (3) Choice And Partnership Approach for shared decision making.
Number of subjects: 0
Study 33318032 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care bundle
Number of subjects: 0
Study 33318123 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal EEG patterns during sleep and wakefulness
Number of subjects: 220
Study 33318123 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG slow wave activity, sleep spindle density, peak frequency of the posterior dominant rhythm
Number of subjects: 220
Study 33318123 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Confusion Assessment Method (CAM) evaluations
Number of subjects: 220
Study 33318163 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 23
Study 33318928 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld multispectral optoacoustic tomography (MSOT)
Number of subjects: 10
Study 33319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks
Number of subjects: 152
Study 33319038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 33319187 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5-10 mg
Number of subjects: 215
Study 33319187 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg
Number of subjects: 215
Study 33319187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 33319318 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-ninhydrin-photometry (PM)
Number of subjects: 0
Study 33319318 — intervention group
Group type: EXPERIMENTAL
Intervention: UHPLC-PITC-tandem mass spectrometry (TMS)
Number of subjects: 0
Study 33319318 — intervention group
Group type: COMPARATOR
Intervention: Both methods (PM and TMS)
Number of subjects: 0
Study 33319318 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS
Number of subjects: 0
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in aortopathy genes with implications for family members
Number of subjects: 225
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in aortopathy genes that would change medical management
Number of subjects: 225
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable secondary findings related to cancer
Number of subjects: 225
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable secondary findings related to other cardiac diseases
Number of subjects: 225
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-actionable findings-pathogenic variants in aortopathy genes that would not change medical management
Number of subjects: 225
Study 33319384 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance
Number of subjects: 225
Study 33319471 — intervention group
Group type: EXPERIMENTAL
Intervention: Third/Fourth OBPM (S3S4/D3D4)
Number of subjects: 802
Study 33319471 — intervention group
Group type: COMPARATOR
Intervention: Second/Third OBPM (S2S3/D2D3)
Number of subjects: 802
Study 33319498 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab treatment
Number of subjects: 537
Study 33319916 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 2319
Study 33320065 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presence of mild, moderate, and confluent emphysema at baseline CT in participants with COPD (1655 participants, 40%)
Number of subjects: 4166
Study 33320065 — intervention group
Group type: COMPARATOR
Intervention: Baseline CT assessment
Number of subjects: 4166
Study 33320065 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary function testing at baseline CT and at 5 years
Number of subjects: 4166
Study 33320065 — intervention group
Group type: COMPARATOR
Intervention: Quantitative inspiratory and expiratory CT at baseline and at 5 years
Number of subjects: 4166
Study 33320102 — intervention group
Group type: EXPERIMENTAL
Intervention: FirstER application-based service
Number of subjects: 1000
Study 33320102 — intervention group
Group type: COMPARATOR
Intervention: Current legacy system
Number of subjects: 1000
Study 33320103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention (twice weekly for 8 months)
Number of subjects: 150
Study 33320103 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 150
Study 33320103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention
Number of subjects: 150
Study 33320245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC), median 1.9 mg/day (IQR 0.6-4.2), mean cumulative prednisone dose 8468 mg, mean duration 44.6 months
Number of subjects: 608
Study 33320245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC), highest cumulative exposure (≥8.4 g)
Number of subjects: 608
Study 33320245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC)
Number of subjects: 608
Study 33320245 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoids (GC)
Number of subjects: 608
Study 33320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (PD)
Number of subjects: 2953
Study 33320729 — intervention group
Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using the robust Integrated Jacobian Formulation (IJF) method
Number of subjects: 77
Study 33321118 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app for sBP measurement
Number of subjects: 965
Study 33321118 — intervention group
Group type: COMPARATOR
Intervention: Reference device - automated oscillometric cuff device
Number of subjects: 965
Study 33321200 — intervention group
Group type: EXPERIMENTAL
Intervention: Open conjunctival implantation of the XEN45 Gel Stent
Number of subjects: 137
Study 33321200 — intervention group
Group type: COMPARATOR
Intervention: Closed conjunctival implantation of the XEN45 Gel Stent
Number of subjects: 137
Study 33322606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement based on 150 mg of resveratrol
Number of subjects: 20
Study 33323025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-18 (IL-18) levels measured in serum by enzyme-linked immunosorbent assay.
Number of subjects: 125
Study 33323025 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver lipid content assessed by liver-to-spleen computed tomography (CT) attenuation ratio.
Number of subjects: 125
Study 33323025 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST) levels.
Number of subjects: 125
Study 33323025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT) levels.
Number of subjects: 125
Study 33323025 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without HIV), 59 participants.
Number of subjects: 125
Study 33323024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART)
Number of subjects: 20
Study 33323208 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle biosensor for phenoxymethylpenicillin monitoring
Number of subjects: 10
Study 33323208 — intervention group
Group type: COMPARATOR
Intervention: Microdialysis for phenoxymethylpenicillin monitoring
Number of subjects: 10
Study 33323208 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle biosensor
Number of subjects: 10
Study 33323208 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle PK
Number of subjects: 10
Study 33323401 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg orally once daily and camrelizumab 200 mg intravenously every 2 weeks
Number of subjects: 105
Study 33323430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV) at 35 Hz, 0.3g, 20 min/day, at least three times/week for 6 months
Number of subjects: 100
Study 33323430 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 100
Study 33323445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multidimensional intervention (6 months duration, including three home visits, six home-based telephone calls, and one peer support session)
Number of subjects: 110
Study 33323445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multidimensional intervention
Number of subjects: 110
Study 33323445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 110
Study 33323462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 59
Study 33323767 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation (HTx) recipients
Number of subjects: 50